TY  - JOUR

T1  - Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma

JO  - Melanoma Research

PY  - 2015/09/03

AU  - Latimer NR

AU  - Amonkar MM

AU  - Stapelkamp C

AU  - Sun P

ED  - 

DO  - DOI: 10.1097/cmr.0000000000000193

PB  - Ovid Technologies (Wolters Kluwer Health)

VL  - 25

IS  - 6

SP  - 528

EP  - 536

Y2  - 2024/12/22

ER  -